Tranexamic acid /ml
ApprovedSmall molecule
Tranexamic acid /ml is one of 22 small molecule programs targeting Mastectomy. It is currently in Approved.
3
Indications
10
Total Trials
2
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Tranexamic acid /ml
IIndonesia University
Approved
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
Epsom Salt
FFresenius Kabi Oncology Ltd.
Preclinical
Zanaflex
LLegacy Health System
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Iron Sulphate
PPierre Fabre Pharma GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Total Knee Arthroplasty2 trials
Use of Tranexamic Acid in the Total Knee Arthroplasty.
Completed·—·N/A·NCT05919615·100 enrolled
Visual Field Infiltration of Tranexamic Acid Reduced the Blood Loss in Total Knee Arthroplasty
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT03934047·120 enrolled
Tranexamic Acid2 trials
INTERVENTION WITH TRANEXAMIC ACID TO REDUCE HAEMORRHAGE DURING LAPAROSCOPIC MYOMECTOMY
Unknown status·—·N/A·NCT04192643·60 enrolled
Hyperpigmentation1 trial
After Cardiac Surgery1 trial
3 more indications
Knee Arthroplasty1 trial
Complication1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tranexamic acid /ml. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- IIndonesia University